Research programme: ezatiostat analogues - MabVax
Latest Information Update: 24 Feb 2023
Price :
$50 *
At a glance
- Originator Telik
- Developer MabVax Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Glutathione transferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Haematological malignancies; Neutropenia
Most Recent Events
- 24 Feb 2023 Discontinued - Preclinical for Haematological malignancies in USA (unspecified route)
- 24 Feb 2023 Discontinued - Preclinical for Neutropenia in USA (unspecified route)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Haematological-malignancies in USA